Investigational / not FDA-approved

CJC-1295 with DAC

Long-acting albumin-binding GHRH(1-29) analog with DAC — investigational; not FDA-approved.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock — SEPARATE from without-DAC / Mod GRF 1-29. This object is CJC-1295 with DAC (Drug Affinity Complex): a tetrasubstituted GHRH(1-29) analog carrying a maleimidopropionyl-Lys linker that covalently binds serum albumin, yielding a long-acting GHRH receptor agonist. PubChem CID 91971820 (also 172966534); formula C165H269N47O46; MW ~3647.2. CAS strings often cited (863288-34-0, 446262-90-4, and others) also appear on without-DAC synonym lists → print CAS as To be confirmed; do not invent one locked CAS for UI. Not sermorelin. Not Mod GRF 1-29 without the DAC linker. No approved indication. Off-label does not apply. There is no label to be off of.

Bottom line

Thin but real human PK/PD exists for the albumin-binding long-acting analog: healthy-adult trials show prolonged GH and IGF-I rises with preserved GH pulsatility. That is a GH-axis stimulation object in volunteers — not an approved indication, not body composition, not anti-aging, and not evidence for without-DAC / Mod GRF 1-29. Preclinical growth rescue appears in a GHRH-knockout mouse paper. Detection/doping papers are not efficacy.

Papers

Identity / discovery — albumin-binding analog

PMID 15817669 — Jetté 2005

Tested: maleimido hGRF(1-29)–albumin bioconjugates; identifies CJC-1295 as tetrasubstituted hGRF(1-29) with Nε-3-maleimidopropionamide lysine; rat GH AUC and multi-day plasma presence.

Does not show: a human therapeutic indication, or results for the without-DAC peptide alone.

Early human — with DAC

PMID 16352683 — Teichman 2006

Tested: CJC-1295 (long-acting GHRH analog that binds albumin; reported multi-day half-life) versus placebo in healthy adults — ascending single-dose and multi-dose PK/PD for GH and IGF-I.

Does not show: an approved therapeutic use, a body-composition claim, or without-DAC / Mod GRF 1-29 results.

PMID 17018654 — Ionescu 2006

Tested: overnight GH pulsatility in healthy young men before and after a single injection of the same long-acting CJC-1295 analog; trough/mean GH and IGF-I.

Does not show: a disease-treatment trial, or that without-DAC Mod GRF produces the same multi-day profile.

PMID 19386527 — Sackmann-Sala 2009

Tested: serum proteomic changes in healthy young men one week after CJC-1295 (long-acting GHRH analog) injection; exploratory GH/IGF-I action biomarkers.

Does not show: clinical benefit, an approved use, or a without-DAC result. Small n.

Preclinical — with DAC

PMID 16822960 — Alba 2006

Tested: once-daily CJC-1295 (long-acting GHRH analog) in GHRH knockout mice for growth normalization.

Does not show: a human growth or adult-body-composition result.

Context, not a grade — detection / narrative

PMID 21871962 — Thomas 2012

Tested: immunoaffinity purification of peptide hormones before LC-MS in doping controls.

Does not show: human therapeutic efficacy.

PMID 26879649 — Knoop 2016

Tested: qualitative identification of GHRH analogs in human plasma.

Does not show: clinical benefit.

PMID 34665524 — Memdouh 2021

Tested: advances in detection of synthetic GHRH analogs.

Does not show: efficacy.

PMID 35298973 — Coppieters 2022

Tested: antibody-free ultrafiltration assay for GHRH analogs in urine.

Does not show: a clinical endpoint.

PMID 42395176 — Dominikowski 2026

Tested: narrative review of performance-enhancing peptides modulating the GH–IGF-I axis; clinical evidence limited relative to marketing/self-administration culture.

Does not show: a new controlled human CJC-1295 with-DAC efficacy trial for physique or anti-aging claims.

What is not established

Any approved indication. Body fat, muscle, recovery, or “anti-aging” as human treatment claims. Equivalence of with-DAC and without-DAC products. A single collision-free CAS for UI. Identity between trial material and any circulating vial labeled only “CJC-1295.”

Selected sources

15817669 16352683 17018654 19386527 16822960 21871962 26879649 34665524 35298973 42395176

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.